Tue, 26 Aug 2008 14:54:38 -0400 PeerView Press http://www.peerviewpress.com Podcast Maker v1.3.3 - http://www.lemonzdream.com/podcastmaker PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. Thought leader perspectives on current clinical advances in medicine. PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. en-us 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY, 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/videopathologyus/vidpodcast_pathology_cme_ce_144.jpg http://www.peerviewpress.com 144 144 Medicine Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Pathology no PeerView Press In this CME activity, experts provide an overview of the latest ASCO/CAP guidelines for HER2 testing in breast cancer. Issues related to specimen handling, tissue fixation, assay validation, laboratory accreditation, and proficiency testing are reviewed, and how the guidelines attempt to address these issues is discussed. The experts also provide answers to common questions to further clarify the new guideline recommendations. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts provide an overview of the latest ASCO/CAP guidelines for HER2 testing in breast cancer. Issues related to specimen handling, tissue fixation, assay validation, laboratory accreditation, and proficiency testing are reviewed, and how the guidelines attempt to address these issues is discussed. The experts also provide answers to common questions to further clarify the new guideline recommendations. http://podcast.peerviewpress.com/videopathologyus/PA03447FC2r231.m4v http://podcast.peerviewpress.com/videopathologyus/PA03447FC2r231.m4v Thu, 01 Nov 2007 13:38:27 -0400 Medicine no 00:28:39 HER2, guidelines, ASCO-CAP guidelines, FISH, IHC, breast cancer, HER2 testing, specimen handling, tissue fixation, assay validation, laboratory accreditation, proficiency testing, HER2-targeted therapy, trastuzumab, Herceptin, lapatinib, Tykerb PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videopathologyus/PA03447FC2CMEinfo_r231.pdf http://podcast.peerviewpress.com/videopathologyus/PA03447FC2CMECEinfo.pdf Thu, 01 Nov 2007 13:35:24 -0400 Medicine no 00:00:00 HER2, guidelines, ASCO-CAP guidelines, FISH, IHC, breast cancer, HER2 testing, specimen handling, tissue fixation, assay validation, laboratory accreditation, proficiency testing, HER2-targeted therapy, trastuzumab, Herceptin, lapatinib, Tykerb PeerView Press In this activity, experts discuss the new guidelines for HER2 testing in breast cancer. The role of HER2-targeted breast cancer therapies is reviewed, issues related to HER2 testing and the rationale for the development of new testing guidelines are discussed, and the updated recommendations from the HER2 testing guidelines in breast cancer are summarized. Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts discuss the new guidelines for HER2 testing in breast cancer. The role of HER2-targeted breast cancer therapies is reviewed, issues related to HER2 testing and the rationale for the development of new testing guidelines are discussed, and the updated recommendations from the HER2 testing guidelines in breast cancer are summarized. http://podcast.peerviewpress.com/videopathologyus/PA03447FC1r230.m4v http://podcast.peerviewpress.com/videopathologyus/PA03447FC1r230.m4v Thu, 22 Feb 2007 13:55:47 -0500 Medicine no 00:33:04 HER2, guidelines, ASCO-CAP guidelines, FISH, IHC, breast cancer, HER2 testing, HER2-targeted therapy, trastuzumab, Herceptin, lapatinib, Tykerb PeerView Press Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/videopathologyus/PA03447FC1CMEinfo_r230.pdf http://podcast.peerviewpress.com/videopathologyus/PA03447FC1CMEinfo_r230.pdf Thu, 22 Feb 2007 13:55:42 -0500 Medicine no 00:00:00 HER2, guidelines, ASCO-CAP guidelines, FISH, IHC, breast cancer, HER2 testing, HER2-targeted therapy, trastuzumab, Herceptin, lapatinib, Tykerb